Overview
Civilian prehospital blood transfusion programs must connect an urgent hemorrhage-treatment clock with a slower evidence clock. The series compares whole blood, PRBC, plasma, crystalloid, and coordinated strategies, then follows sourcing, cold-chain control, training, handoff, and review. It shows how a locally governed, auditable capability can act under uncertainty without claiming universal mortality superiority for a product or strategy, while identifying the populations, EMS systems, and comparisons still needing stronger research.
Learning outcomes
- The AHRQ review did not establish consistent mortality superiority for any one blood or fluid intervention across civilian prehospital systems.
- The ARC Bundle showed a promising discharge-mortality signal, but nonrandomized evidence cannot isolate the effects of its components, speed, or system factors.
- Whole blood may simplify administration; components may improve inventory flexibility; plasma supports coagulation; crystalloid remains a bounded fallback.
- Responsible deployment requires defined indications, reliable supply, cold-chain control, trained oversight, handoff, and case-level learning.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
Does the evidence show that whole blood is better than component therapy before hospital arrival?
No; the reviewed evidence is insufficient to establish that whole blood is better than component therapy in civilian prehospital care.
What makes a civilian prehospital blood transfusion program ready to operate?
Readiness requires a defined indication, a usable product and cold chain, trained clinicians with medical oversight, and reliable transport, handoff, and review. These conditions make the pathway auditable, not proven to reduce mortality.
Why can early blood treatment matter when mortality evidence is uncertain?
Early treatment may interrupt hemorrhagic shock before hospital arrival, but physiologic improvement or faster delivery does not by itself prove lower later mortality. Outcome timing, later care, and system differences also shape the evidence.
What does the ARC Bundle evidence actually show?
The ARC Bundle was associated with lower hospital-discharge mortality than usual care in three nonrandomized studies. It combined PRBC, tranexamic acid, calcium, and rapid infusion, so the evidence cannot identify which element or system factor drove the association.